February 28, 2024 07:27 AM EST
Deals

Ab­b­Vie bets $48M up­front for ear­ly-stage an­ti­body tar­get­ing chron­ic in­flam­ma­tion

Katherine Lewin

News Reporter

Ab­b­Vie is mak­ing good on its plans to search for new mech­a­nisms of ac­tion, this time with French biotech OSE Im­munother­a­peu­tics for a mon­o­clon­al an­ti­body …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times